FDA’s Center for Drug Evaluation and Research’s (CDER) Office of New Drugs (OND) recently launched a pilot program on Novel Excipient Review. The pilot program offers a new pathway for drug manufacturers to obtain FDA review of certain novel excipients (inactive ingredients)
Similar Posts
PDUFA VII Commitment: An Assessment of the Sentinel System (2022 to 2024)
PDUFA VII Commitment: An Assessment of the Sentinel System (2022 to 2024)Animal Model Qualification Program | AMQP
Information for requestors interested in submitting animal models for qualification to FDA’s Drug Development Tool (DDT) Programs.Commissioner’s National Priority Voucher (CNPV) Pilot Program
FDA Commissioner’s National Priority Voucher Program. The Commissioner’s National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.CDER and CBER accept first submission to ISTAND Pilot Program
FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted the agency’s first submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.Media Networks Sydney Pty Limited – 687044 – 09/18/2024
Failure to Register and ListMedisourceRx. Los Alamitos, CA. 483 issued 06/10/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/10/2025
Short Title (70 char) MedisourceRx. Los Alamitos, CA. 483 issued 06/10/2025
FEI Number 3013316698
Firm Name MedisourceRx
Record Type 483
State CA